ANDA 212821, held by Huons. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 212821 (Lidocaine Hydrochloride), held by Huons, was first approved by FDA on May 7, 2020, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine Hydrochloride Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 7, 2020 | Original application | Approved | None posted |
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Oct 18, 2023 | Supplement 4Manufacturing | Approved | None posted |
| Jun 1, 2021 | Supplement 1Manufacturing · Standard review | Approved | None posted |
| May 7, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters